Last updated on July 2019

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).


Brief description of study

Primary objective:

To evaluate the efficacy of subcutaneous (SC) administration of tralokinumab compared with placebo in treating adolescent subjects (age 12 to <18 years) with moderate-to-severe AD.

Secondary objectives:

To evaluate the efficacy of tralokinumab on severity and extent of AD, itch, and health-related quality of life compared with placebo.

To investigate the safety, immunogenicity, and tolerability of SC administration of tralokinumab compared with placebo when used to treat adolescent subjects (age 12 to <18 years) with moderate-to-severe AD.

Clinical Study Identifier: NCT03526861

Find a site near you

Start Over

LEO Pharma Investigational Site

Birmingham, AL United States
  Connect »

LEO Pharma Investigational Site

Fort Smith, AR United States
  Connect »

Leo Pharma Investigational Site

Fountain Valley, CA United States
  Connect »

LEO Pharma Investigational Site

Los Angeles, CA United States
  Connect »

LEO Pharma Investigational Site

San Francisco, CA United States
  Connect »

LEO Pharma Investigational Site

Louisville, KY United States
  Connect »

LEO Pharma Investigational Site

Baton Rouge, LA United States
  Connect »

LEO Pharma Investigational Site

Minneapolis, MN United States
  Connect »

LEO Pharma Investigational Site

East Windsor, NJ United States
  Connect »

LEO Pharma Investigational Site

Stony Brook, NY United States
  Connect »

LEO Pharma Investigational Site

High Point, NC United States
  Connect »

LEO Pharma Investigational Site

Philadelphia, PA United States
  Connect »

Leo Pharma Investigational Site

North Charleston, SC United States
  Connect »

LEO Pharma Investigational Site

Evansville, TN United States
  Connect »

Leo Pharma Investigational Site

Murfreesboro, TN United States
  Connect »

Leo Pharma Investigational Site

San Antonio, TX United States
  Connect »